Opioid Use Disorder Clinical Trials

135 studies are recruiting for opioid use disorder in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

   This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone …

   Stage

   Phase 2

   Ages

   21 to 70

   Site

   Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT06067737 on ClinicalTrials.gov

2. Adversity, Brain and Opioid Use Study

   The way people process and remember information may be related to adverse childhood experiences and Opioid Use Disorder symptoms. The purpose of this project is to examine brain function and performance during learning and memory tasks in adults. The study will compare measures of learning and memo…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   University of Michigan, Ann Arbor, Michigan

   Run by

   University of Michigan

   See if you can join NCT06355778 on ClinicalTrials.gov

3. Identifying Biomarkers Related to Opioid Use and Pain Response Following Traumatic Injury and Surgery

   The mechanisms leading to opioid tolerance or dependence are not well understood and there are currently no biomarkers for predicting who is at risk for development of OUD. The purpose of this project is to support the feasibility of detecting a miRNA bio-behavioral signature of opioid misuse risk …

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Diego, La Jolla, California

   Run by

   University of California, San Diego

   See if you can join NCT07693270 on ClinicalTrials.gov

4. Combined THC and CBD for OUD and Chronic Pain

   The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (OUD) and chronic pa…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Connecticut Mental Health Center, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT06544291 on ClinicalTrials.gov

5. Methadone Patient Access to Collaborative Treatment

   The trial of Methadone Patient Access to Collaborative Treatment (MPACT) will establish the impact of the intervention on patient outcomes of methadone treatment retention and in treatment overdose. It will also establish the impact of patient and staff trauma symptoms and clinic practice change on…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Arizona College of Nursing, Tucson, Arizona

   Run by

   University of Arizona

   See if you can join NCT06556602 on ClinicalTrials.gov

6. Project STRONGER: Stepped Care for Opioid Use Disorder Treatment Engagement and Recovery

   Using a hybrid type 1 effectiveness-implementation approach, this study aims to evaluate the impact of a novel stepped care model ("PCT+2HOPE") versus treatment as usual (TAU) on increasing retention in community-based medication for opioid use disorder (MOUD) treatment among women who have experie…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Liberation Programs, Bridgeport, Connecticut

   Locations

   3 in total

   Run by

   Yale University

   See if you can join NCT07115030 on ClinicalTrials.gov

7. Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

   The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania Center for Studies of Addiction, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT06379984 on ClinicalTrials.gov

8. Autobiographical Memory in Opioid Use Disorder

   The research study is being conducted to better understand memory function in people with opioid use disorder (OUD) and whether memory training can improve the symptoms and lives of people with OUD. Further, this study seeks to identify how brain and heart activity contribute to memory function and…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT06643988 on ClinicalTrials.gov

9. Psilocybin on Brain Mechanisms of Motivation in OUD

   The goal of this study is to test addiction-related brain circuitry (motivation/reward and inhibition) as well as neurocognitive circuitry prior to and following low or high dose psilocybin (PEX010 from Filament). Using fMRI, brain circuits will be examined that are relevant to drug relapse as well…

   Stage

   Phase 2

   Ages

   18 to 60

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT06810310 on ClinicalTrials.gov

10. Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

    The goal of this clinical trial is to learn about how certain medications used to treat insomnia (e.g., Lemborexant) impact sleep, mood, and behavior in men and women with Opioid Use Disorder who are taking prescribed buprenorphine. The main questions it aims to answer are: 1. What is the effect of…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VCU Institute for Drug and Alcohol Studies, Richmond, Virginia

    Run by

    Virginia Commonwealth University

    See if you can join NCT06981195 on ClinicalTrials.gov

11. Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

    Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation. Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy. Secon…

    Stage

    Phase 1

    Ages

    21 to 65

    Site

    University of Wisconsin, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT04161066 on ClinicalTrials.gov

12. Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

    This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the [11C]-UCB-J radiotracer while inpatient.

    Stage

    Phase 1

    Ages

    25 to 55

    Site

    Yale University, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT06160284 on ClinicalTrials.gov

13. An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)

    The purpose of this study is to address the gap in maternal OUD treatment and infant neonatal opioid withdrawal syndrome care. The research team will develop a treatment model and a set of strategies to provide evidence-based OUD treatment to postpartum mothers in NICUs. First, the investigators wi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    3 in total

    Run by

    University of Pennsylvania

    See if you can join NCT06576323 on ClinicalTrials.gov

14. Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder

    The overall goal of this study is to investigate the added benefit of a neuromodulation intervention in individuals taking medication for treatment for Opioid Use Disorder(OUD).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Minnesota, Minneapolis, Minnesota

    Run by

    University of Minnesota

    See if you can join NCT07158853 on ClinicalTrials.gov

15. Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic

    "Gold-standard" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide "whole-patient" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulatio…

    Stage

    Not phased

    Ages

    18 and older

    Site

    VA Medical Center, Boston, Massachusetts

    Run by

    Boston University

    See if you can join NCT07232641 on ClinicalTrials.gov

16. tDCS to Decrease Opioid Relapse (UH3)

    Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided v…

    Stage

    Not phased

    Ages

    21 to 60

    Site

    Butler Hospital, Providence, Rhode Island

    Run by

    Butler Hospital

    See if you can join NCT06432465 on ClinicalTrials.gov

17. Using Clinical Decision Support to Provide Social Risk-Informed Care for Opioid Use Disorder in the Emergency Department

    The overarching goal of this proposal is to integrate patient social risk information into an existing electronic health record (EHR)-based clinical decision support (CDS) tool (CDSv1) to facilitate emergency department (ED)-initiated, social risk-informed opioid use disorder (OUD) medication treat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT06872190 on ClinicalTrials.gov

18. Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department

    Main study objective: compare long-term buprenorphine treatment outcomes for patients who start buprenorphine for opioid use disorder (OUD) in the emergency department and are then referred to get outpatient buprenorphine treatment either via telehealth or at an in-person clinic. Researchers will: …

    Stage

    Not phased

    Ages

    18 and older

    Site

    El Centro Regional Medical Center Emergency Department, El Centro, California

    Locations

    3 in total

    Run by

    University of California, Davis

    See if you can join NCT06961058 on ClinicalTrials.gov

19. Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

    The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) and/or other Substance Use Disorders (SUDs) by assessing its safety and tolerability in s…

    Stage

    Not phased

    Ages

    18 to 60

    Site

    University of Maryland, Baltimore, Baltimore, Maryland

    Locations

    4 in total

    Run by

    InSightec

    See if you can join NCT04197921 on ClinicalTrials.gov

20. Smartphones for Opiate Addiction Recovery

    Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates th…

    Stage

    Phase 3

    Ages

    18 to 85

    Site

    NYU Langone, New York, New York

    Locations

    2 in total

    Run by

    NYU Langone Health

    See if you can join NCT05033028 on ClinicalTrials.gov

21. Measuring Acute Drug Demand in Humans

    This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.

    Stage

    EARLY_Phase 1

    Ages

    18 to 65

    Site

    General Clinical Research Center, Baltimore, Maryland

    Run by

    University of Maryland, Baltimore

    See if you can join NCT05829655 on ClinicalTrials.gov

22. Resilience Among Individuals With Opioid Use Disorder

    The goal of this clinical trial is to develop a human laboratory model of resilience in people with opioid use disorder (OUD). The investigators aim to learn if objective tasks that measure cognitive, emotional, and control aspects of resilience match up with self-reported resilience during stress …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Johns Hopkins University Bayview Medical Campus, Baltimore, Maryland

    Locations

    2 in total

    Run by

    Johns Hopkins University

    See if you can join NCT06954402 on ClinicalTrials.gov

23. Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD

    The goal of this clinical trial is to reduce heavy drinking and enhance medication for opioid use disorder (MOUD) outcomes in individuals receiving MOUD. The main questions it aims to answer are: * Does the brief, digitally-enhanced, virtual psychotherapeutic intervention, called Managing Physical …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Ohio State University, Columbus, Ohio

    Run by

    Ohio State University

    See if you can join NCT06718491 on ClinicalTrials.gov

24. Cannabis and Opioid Use Disorder

    This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    Center on Drug and Alcohol Research, Lexington, Kentucky

    Run by

    Shanna Babalonis, PhD

    See if you can join NCT05729932 on ClinicalTrials.gov

25. Opioid Use Disorder and Pain

    The goal of this observational study is to characterize the brain processes of pain avoidance learning dysfunctions in individuals with opioid use disorder (OUD). The main questions it aims to answer are: Compared with healthy controls, do those with OUD exhibit impaired avoidance learning in respo…

    Stage

    Not phased

    Ages

    21 to 60

    Site

    Connecticut Mental Health Center, S105, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT06800703 on ClinicalTrials.gov